Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs.
Amyotrophic lateral sclerosis
Biomarkers
Brainstem
MRI
Motor neuron disorder
Non-invasive ventilation
Spinal cord
Spirometry
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
23
08
2023
accepted:
03
10
2023
revised:
01
10
2023
medline:
27
2
2024
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
ppublish
Résumé
Respiratory complications resulting from motor neurons degeneration are the primary cause of death in amyotrophic lateral sclerosis (ALS). Predicting the need for non-invasive ventilation (NIV) in ALS is important for advance care planning and clinical trial design. The aim of this study was to assess the potential of quantitative MRI at the brainstem and spinal cord levels to predict the need for NIV during the first six months after diagnosis. Forty-one ALS patients underwent MRI and spirometry shortly after diagnosis. The need for NIV was monitored according to French health guidelines for 6 months. The performance of four regression models based on: clinical variables, brainstem structures volumes, cervical spinal measurements, and combined variables were compared to predict the need for NIV within this period. Both the clinical model (R Our study shows that brainstem volumes and spinal cord area are promising measures to predict respiratory intervention needs in ALS.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory complications resulting from motor neurons degeneration are the primary cause of death in amyotrophic lateral sclerosis (ALS). Predicting the need for non-invasive ventilation (NIV) in ALS is important for advance care planning and clinical trial design. The aim of this study was to assess the potential of quantitative MRI at the brainstem and spinal cord levels to predict the need for NIV during the first six months after diagnosis.
METHODS
METHODS
Forty-one ALS patients underwent MRI and spirometry shortly after diagnosis. The need for NIV was monitored according to French health guidelines for 6 months. The performance of four regression models based on: clinical variables, brainstem structures volumes, cervical spinal measurements, and combined variables were compared to predict the need for NIV within this period.
RESULTS
RESULTS
Both the clinical model (R
CONCLUSIONS
CONCLUSIONS
Our study shows that brainstem volumes and spinal cord area are promising measures to predict respiratory intervention needs in ALS.
Identifiants
pubmed: 37910250
doi: 10.1007/s00415-023-12045-x
pii: 10.1007/s00415-023-12045-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235-1246Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Lechtzin N, Wiener CM, Clawson L et al (2001) Hospitalization in amyotrophic lateral sclerosis, causes, costs, and outcomes. Neurology 56:753–757. https://doi.org/10.1212/WNL.56.6.753
doi: 10.1212/WNL.56.6.753
pubmed: 11274310
Pinto S, Carvalho M (2014) Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegenerative Disease Manag 4:83–102. https://doi.org/10.2217/nmt.13.74
doi: 10.2217/nmt.13.74
Pruitt B (2008) Loosening the bonds of restrictive lung disease. Nursing 38:34–39. https://doi.org/10.1097/01.NURSE.0000327490.70569.bc
doi: 10.1097/01.NURSE.0000327490.70569.bc
pubmed: 18648298
Benditt JO (2002) Respiratory complications of amyotrophic lateral sclerosis. Sem Respirat Crit Care Med 23:239–247. https://doi.org/10.1055/s-2002-33032
doi: 10.1055/s-2002-33032
Corcia P, Pradat PF, Salachas F et al (2008) Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 9:59–62. https://doi.org/10.1080/17482960701656940
doi: 10.1080/17482960701656940
pubmed: 17924236
Pinto S, de Carvalho M (2015) The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 16:120–123. https://doi.org/10.3109/21678421.2014.952641
doi: 10.3109/21678421.2014.952641
pubmed: 25205208
Andersen PM, Abrahams S, Borasio GD et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol 19:360–375. https://doi.org/10.1111/j.1468-1331.2011.03501.x
doi: 10.1111/j.1468-1331.2011.03501.x
pubmed: 21914052
Miller RG, Jackson CE, Kasarskis EJ et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218–1226. https://doi.org/10.1212/WNL.0b013e3181bc0141
doi: 10.1212/WNL.0b013e3181bc0141
pubmed: 19822872
pmcid: 2764727
Bourke SC, Tomlinson M, Williams TL et al (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5:140–147. https://doi.org/10.1016/s1474-4422(05)70326-4
doi: 10.1016/s1474-4422(05)70326-4
pubmed: 16426990
Leonardis L, Dolenc Grošelj L, Vidmar G (2012) Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol 19:1518–1524. https://doi.org/10.1111/j.1468-1331.2012.03754.x
doi: 10.1111/j.1468-1331.2012.03754.x
pubmed: 22594630
Vandoorne E, Vrijsen B, Belge C et al (2016) Noninvasive ventilation in amyotrophic lateral sclerosis: effects on sleep quality and quality of life. Acta Clin Belg 71:389–394. https://doi.org/10.1080/17843286.2016.1173941
doi: 10.1080/17843286.2016.1173941
pubmed: 27112318
Ackrivo J, Hsu JY, Hansen-Flaschen J et al (2021) Noninvasive ventilation use is associated with better survival in amyotrophic lateral sclerosis. Ann Am Thorac Soc 18:486–494. https://doi.org/10.1513/AnnalsATS.202002-169OC
doi: 10.1513/AnnalsATS.202002-169OC
pubmed: 32946280
pmcid: 7919153
Al-Chalabi A, Chiò A, Merrill C et al (2021) Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J Neurol Neurosurg Psychiatry 92:165–171. https://doi.org/10.1136/jnnp-2020-323271
doi: 10.1136/jnnp-2020-323271
pubmed: 33109706
Fang T, Al Khleifat A, Meurgey JH et al (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17:416–422. https://doi.org/10.1016/s1474-4422(18)30054-1
doi: 10.1016/s1474-4422(18)30054-1
pubmed: 29525492
pmcid: 5899963
Georges M, Perez T, Rabec C et al (2022) Proposals from a French expert panel for respiratory care in ALS patients. Respirat Med Res 81:100901. https://doi.org/10.1016/j.resmer.2022.100901
doi: 10.1016/j.resmer.2022.100901
Ackrivo J, Hansen-Flaschen J, Wileyto EP et al (2019) Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respirat J. https://doi.org/10.1183/13993003.02237-2018
doi: 10.1183/13993003.02237-2018
Grolez G, Kyheng M, Lopes R et al (2018) MRI of the cervical spinal cord predicts respiratory dysfunction in ALS. Sci Rep 8:1828. https://doi.org/10.1038/s41598-018-19938-2
doi: 10.1038/s41598-018-19938-2
pubmed: 29379040
pmcid: 5789036
Clarke JL, Jackson JH (1867) On a case of muscular atrophy, with disease of the spinal cord and medulla oblongata. Medico-Chirurgical Transact 50(489–98):1. https://doi.org/10.1177/095952876705000122
doi: 10.1177/095952876705000122
Brettschneider J, Del Tredici K, Toledo JB et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20–38. https://doi.org/10.1002/ana.23937
doi: 10.1002/ana.23937
pubmed: 23686809
pmcid: 3785076
Brooks BR, Miller RG, Swash M et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 1:293–299. https://doi.org/10.1080/146608200300079536
doi: 10.1080/146608200300079536
Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13–21. https://doi.org/10.1016/s0022-510x(99)00210-5
doi: 10.1016/s0022-510x(99)00210-5
pubmed: 10540002
Fischl B (2012) FreeSurfer. Neuroimage 62:774–781. https://doi.org/10.1016/j.neuroimage.2012.01.021
doi: 10.1016/j.neuroimage.2012.01.021
pubmed: 22248573
Iglesias JE, Van Leemput K, Bhatt P et al (2015) Bayesian segmentation of brainstem structures in MRI. Neuroimage 113:184–195. https://doi.org/10.1016/j.neuroimage.2015.02.065
doi: 10.1016/j.neuroimage.2015.02.065
pubmed: 25776214
De Leener B, Lévy S, Dupont SM et al (2017) SCT: Spinal Cord Toolbox, an open-source software for processing spinal cord MRI data. Neuroimage 145:24–43. https://doi.org/10.1016/j.neuroimage.2016.10.009
doi: 10.1016/j.neuroimage.2016.10.009
pubmed: 27720818
Fonov VS, Le Troter A, Taso M et al (2014) Framework for integrated MRI average of the spinal cord white and gray matter: the MNI-Poly-AMU template. Neuroimage 102(Pt 2):817–827. https://doi.org/10.1016/j.neuroimage.2014.08.057
doi: 10.1016/j.neuroimage.2014.08.057
pubmed: 25204864
Deng X, Hao Y, Xiao B et al (2020) Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population. J Clin Neurosci 72:63–67. https://doi.org/10.1016/j.jocn.2020.01.030
doi: 10.1016/j.jocn.2020.01.030
pubmed: 31956088
De Carvalho M, Swash M, Pinto S (2019) Diaphragmatic neurophysiology and respiratory markers in ALS. Front Neurol 10:143. https://doi.org/10.3389/fneur.2019.00143
doi: 10.3389/fneur.2019.00143
pubmed: 30846968
pmcid: 6393326
Bede P, Hardiman O (2014) Lessons of ALS imaging: pitfalls and future directions—a critical review. NeuroImage Clinical 4:436–443. https://doi.org/10.1016/j.nicl.2014.02.011
doi: 10.1016/j.nicl.2014.02.011
pubmed: 24624329
pmcid: 3950559
Paquin M, El Mendili MM, Gros C et al (2018) Spinal cord gray matter atrophy in amyotrophic lateral sclerosis. Am J Neuroradiol 39:184–192. https://doi.org/10.3174/ajnr.A5427
doi: 10.3174/ajnr.A5427
pubmed: 29122760
pmcid: 7410702
Bede P, Chipika RH, Finegan E et al (2019) Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: a longitudinal neuroimaging study. NeuroImage Clinical 24:102054. https://doi.org/10.1016/j.nicl.2019.102054
doi: 10.1016/j.nicl.2019.102054
pubmed: 31711033
pmcid: 6849418
Milella G, Introna A, Ghirelli A et al (2022) Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis. NeuroImage Clin 34:103015. https://doi.org/10.1016/j.nicl.2022.103015
doi: 10.1016/j.nicl.2022.103015
pubmed: 35561555
pmcid: 9111981
Li H, Zhang Q, Duan Q et al (2021) Brainstem involvement in amyotrophic lateral sclerosis: a combined structural and diffusion tensor MRI analysis. Front Neurosci 15:675444. https://doi.org/10.3389/fnins.2021.675444
doi: 10.3389/fnins.2021.675444
pubmed: 34149349
pmcid: 8206526
Tan EL, Bede P, Pradat PF (2023) Promises and pitfalls of imaging-based biomarkers in motor neuron diseases. Curr Opin Neurol 36:346–352. https://doi.org/10.1097/wco.0000000000001169
doi: 10.1097/wco.0000000000001169
pubmed: 37382064
Witzel S, Frauhammer F, Steinacker P et al (2021) Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration 10:31. https://doi.org/10.1186/s40035-021-00257-y
doi: 10.1186/s40035-021-00257-y
pubmed: 34433481
pmcid: 8390195
Meyer T, Schumann P, Weydt P et al (2023) Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice. Muscle Nerve 67:515–521. https://doi.org/10.1002/mus.27818
doi: 10.1002/mus.27818
pubmed: 36928619
Miller TM, Cudkowicz ME, Genge A et al (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387:1099–1110. https://doi.org/10.1056/NEJMoa2204705
doi: 10.1056/NEJMoa2204705
pubmed: 36129998
Blasco H, Vourc’h P, Pradat PF et al (2016) Further development of biomarkers in amyotrophic lateral sclerosis. Expert Rev Neurother 16:853–868. https://doi.org/10.1080/14737159.2016.1199277
doi: 10.1080/14737159.2016.1199277
Schuster C, Hardiman O, Bede P (2017) Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol 17:73. https://doi.org/10.1186/s12883-017-0854-x
doi: 10.1186/s12883-017-0854-x
pubmed: 28412941
pmcid: 5393027
Khamaysa M, Lefort M, Pélégrini-Issac M et al (2023) Comparison of spinal magnetic resonance imaging and classical clinical factors in predicting motor capacity in amyotrophic lateral sclerosis. J Neurol 270:3885–3895. https://doi.org/10.1007/s00415-023-11727-w
doi: 10.1007/s00415-023-11727-w
pubmed: 37103756
El Mendili MM, Verschueren A, Ranjeva JP et al (2023) Association between brain and upper cervical spinal cord atrophy assessed by MRI and disease aggressiveness in amyotrophic lateral sclerosis. Neuroradiology. https://doi.org/10.1007/s00234-023-03191-0
doi: 10.1007/s00234-023-03191-0
pubmed: 37458788
Manera U, Torrieri MC, Moglia C et al (2021) Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 22:33–39. https://doi.org/10.1080/21678421.2021.1887263
doi: 10.1080/21678421.2021.1887263
pubmed: 34348536